Blood

Article	Citations
COVID-19 and its implications for thrombosis and anticoagulation	1711
Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome	1030
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection	949
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data	823
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN	814
Platelet gene expression and function in patients with COVID-19	711
Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19	562
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia	516
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee	515
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial	460
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients	456
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial	420
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party	306
Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis	288
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study	279
Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition	275
Venous thromboembolism in cancer patients: a population-based cohort study	274
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report	265
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients	243
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19	237
Outcomes of COVID-19 in patients with CLL: a multicenter international experience	235
Pediatric hemophagocytic lymphohistiocytosis	220
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure	204
Overview of Castleman disease	201
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia	197

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS	189
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era	188
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia	182
Postdischarge thrombosis and hemorrhage in patients with COVID-19	181
Glucose-6-phosphate dehydrogenase deficiency	171
Langerhans cell histiocytosis	168
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial	167
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma	166
The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice	160
Antibody-induced procoagulant platelets in severe COVID-19 infection	158
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies	155
Postdischarge venous thromboembolism following hospital admission with COVID-19	154
NPM1-mutated acute myeloid leukemia: from bench to bedside	151
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI	150
Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C	146
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs	146
Therapeutic options in VEXAS syndrome: insights from a retrospective series	145
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study	140
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set	138
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells	137
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA	136
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma	134
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies	134
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas	133
Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry	131
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome	131
Prothrombotic immune thrombocytopenia after COVID-19 vaccination	130
Management of AL amyloidosis in 2020	129
Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes	126
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results	125
Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2	121
Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study	120
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose	119
Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset	118
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study	118
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy	115
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial	115
Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion	115
Novel somatic mutations in UBA1 as a cause of VEXAS syndrome	114
High total metabolic tumor volume at baseline predicts survival independent of response to therapy	113
Developmental trajectory of prehematopoietic stem cell formation from endothelium	112
Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms	112
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype	112
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis	111
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies	110
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study	110
Diamond-Blackfan anemia	109
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines	108
Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation	107
Use of convalescent plasma in hospitalized patients with COVID-19: case series	107

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results	106
SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein	105
Association of clonal hematopoiesis with chronic obstructive pulmonary disease	105
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma	105
Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study	103
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells	103
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis	100
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression	99
Redefining outcomes in immune TTP: an international working group consensus report	99
Erdheim-Chester disease	97
Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults	96
Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy	96
Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein	95
The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD	95
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity	94
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma	94
A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma	93
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial	93
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination	93
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial	93
A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP	92
How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation	92
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin	91
Real-world experience with caplacizumab in the management of acute TTP	90
piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL	90
Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR	89
How I treat relapsed acute lymphoblastic leukemia in the pediatric population	89
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma	89
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study	89
New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis	89
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study	88
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis	88
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results	88
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know	87
Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor	87
Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CA	87
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis	86
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma	86
HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis	86
COVID-19 coagulopathy, thrombosis, and bleeding	86
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells	86
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma	86
Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report	85
YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner	84
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort	84
Cold agglutinin disease revisited: a multinational, observational study of 232 patients	84
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma	84
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel	83
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia	83
Cancer immunoediting and immune dysregulation in multiple myeloma	83
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome	83
Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study	83
Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated withpiggyBac-modified CD19 CAR T cells	81
Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity	81
A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myel	81
A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma	81
Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal	80
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax	80
A critical role of nuclear m6A reader YTHDC1 in leukemogenesis by regulating MCM complex–mediated DNA replication	80
BCL2 and MCL1 inhibitors for hematologic malignancies	79
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies	79
Cancer spectrum and outcomes in the Mendelian short telomere syndromes	78
Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group	78
Platelets and extracellular vesicles and their cross talk with cancer	78
Neutrophil extracellular traps promote tPA-induced brain hemorrhage via cGAS in mice with stroke	78
Leukemia secondary to myeloproliferative neoplasms	77
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma	77
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells	77
Emicizumab for the treatment of acquired hemophilia A	77
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up	77
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma	76
The relationship between ABO blood group, von Willebrand factor, and primary hemostasis	76
CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity	75
Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia	75
Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an	75
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?	74
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias	73
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma	73
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial	73
Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis	73

ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic	72
Genetics of progression from MDS to secondary leukemia	72
Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production	72
Comprehensive analyses of B-cell compartments across the human body reveal novel subsets and a gut-resident memory phenotype	71
Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL	71
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study	71
Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation	70
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL	70
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML	70
Neutrophil extracellular traps promote fibrous vascular occlusions in chronic thrombosis	70
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA	69
No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation	69
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL	69
Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues	68
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy	68
Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial	68
Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)	68
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study	67
Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder	67
COVID-19 in patients with hematologic malignancy	67
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia	67
Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment	66
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial	66
Excess heme upregulates heme oxygenase 1 and promotes cardiac ferroptosis in mice with sickle cell disease	66
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas	66
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib	66
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL	65
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax	65
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma	65
Genomic profiling for clinical decision making in lymphoid neoplasms	64
Plasminogen: an enigmatic zymogen	64
Cytokines and costimulation in acute graft-versus-host disease	64
Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers	64
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Trans	64
An intact gut microbiome protects genetically predisposed mice against leukemia	64
How I treat relapsed or refractory AML	63
Vasculopathy in COVID-19	63
How I treat cold agglutinin disease	63
How I treat paroxysmal nocturnal hemoglobinuria	63
Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with	63
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria	63
Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients	63
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia	63
Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency	63
High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML	63
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL	63
T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis	62
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults	62
CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma	62
A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial	62
Congenital dyserythropoietic anemias	62
Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis	62
Adult blood stem cell localization reflects the abundance of reported bone marrow niche cell types and their combinations	62
Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets	61
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals	61
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE	61
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial	60
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition	60
Mutational landscape of gray zone lymphoma	60
Germline TET2 loss of function causes childhood immunodeficiency and lymphoma	59
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial	59
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?	59
Highly accurate differentiation of bone marrow cell morphologies using deep neural networks on a large image data set	59
TET2-mutant clonal hematopoiesis and risk of gout	59
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemi	59
Lessons to learn from tumor-educated platelets	59
Single-cell analysis of ploidy and the transcriptome reveals functional and spatial divergency in murine megakaryopoiesis	59
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma	59
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation	59
Primary central nervous system lymphoma	59
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes	58
Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant	58
Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies	58
BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice	58
Relationship between clone metrics and clinical outcome in clonal cytopenia	58
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms	58
EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity	58
Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity	57
Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors	57
Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients	57
CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease	57
Molecular classification improves risk assessment in adult BCR-ABL1–negative B-ALL	57
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR	57
CD63 is regulated by iron via the IRE-IRP system and is important for ferritin secretion by extracellular vesicles	57
Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria	57
Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans	57
Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition	57
The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications	56
Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma	56
Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis	55
Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN	55
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma	55
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab	55
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity	55
Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial	55